Latest Kaiser Health News Stories
The Democratic presidential ticket is complete, with Joe Biden’s selection of California Sen. Kamala Harris as his running mate. Health has not been a major issue for Harris, whose career priority has been the criminal justice system. But expect Republicans to pounce on her on-again, off-again support for “Medicare for All.” Meanwhile, with Congress still in a stalemate over another round of COVID-19 relief, President Donald Trump is trying to use his executive power to do what lawmakers have not — with mixed success. Kimberly Leonard of Business Insider, Joanne Kenen of Politico and Mary Agnes Carey of KHN join KHN’s Julie Rovner to discuss this and more. Plus, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
Experts say folks 60 and up must continue to limit exposure in the years to come — even after there is a vaccine for COVID-19.
Teams are starting to test vaccines using messenger RNA or chimpanzee cold viruses to inoculate humans. Will their benefits last?
This statement is taken from a video in which a group of doctors air unproven conspiracy theories about the coronavirus. Dr. Immanuel’s claims were among the most inaccurate. And, before it was removed from social media platforms, thee video was viewed millions of times. President Donald Trump retweeted it.
President Donald Trump’s sobering view of COVID-19 didn’t last long – this week, he was back to pushing hydroxychloroquine, a drug that has been shown not to work in treating the virus. Meanwhile, Republicans on Capitol Hill are still scrambling to agree among themselves and with the White House on the next coronavirus relief bill, as both a moratorium on evictions and extra unemployment payments expire. And the debate over drug prices, which was going to be one of the biggest health issues of this election year, makes a brief appearance. Alice Miranda Ollstein of Politico, Mary Ellen McIntire of CQ Roll Call and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss this and more. Also, Rovner interviews KHN’s Markian Hawryluk, who wrote the latest KHN-NPR “Bill of the Month” story about a surprise bill from a surprise surgical assistant.
The FDA must approve any coronavirus vaccine before it’s widely distributed, but political pressure could cloud the decision.
Newsletter editor Lauren Olsen wades through hundreds of health care policy stories each week, so you don’t have to.
Under ordinary circumstances, these phases of vaccine development can take years to complete. But now, during the age of coronavirus, the timeline is being shortened. Here’s an inventory of where things stand.
A rule finalized this spring by the Trump administration permits employers and insurers not to apply drug company copayment assistance toward enrollees’ deductibles and out-of-pocket maximums for any drug.
The Trump administration rolled back protections for transgender patients just days before the Supreme Court cemented LGBTQ rights under the Civil Rights Act. So, what now? Meanwhile, coronavirus politics reaches beyond health care settings. Anna Edney of Bloomberg News, Tami Luhby of CNN and Shefali Luthra of KHN join KHN’s Julie Rovner to discuss this and more. Also, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
KHN executive editor Damon Darlin wades through mounds of health care policy stories — so you don’t have to.
Sen. Kyrsten Sinema has received almost $100,000 from drug companies in the current election cycle, a KHN analysis shows, one of the largest cash hauls in Congress. And it’s only her first term.
A Kaiser Health News database tracks campaign donations from drugmakers over the past 10 years.
Trials are an immense undertaking involving tens of thousands of participants. They’re likely to start this summer — but don’t expect quick results. And what’s a successful result, anyway?
Vaccines and antivirals have long been an afterthought but Johnson & Johnson and other firms are widely publicizing how they might stop COVID 19.
Thousands of researchers worldwide are looking for a treatment that will go beyond what remdesivir can do for COVID patients.
KHN’s Julie Rovner joins a panel of journalists on “1A” to talk about promising results in a study of the drug remdesivir and other developments in the battle against the coronavirus.
The Supreme Court this week, in an 8-1 decision, ruled that insurers are due the roughly $12 billion that Congress several years ago tried to cut off in payments under the Affordable Care Act’s “risk corridors” provision. And while the COVID-19 pandemic continues to rage in many places around the country, states are starting to reopen their economies at the urging of President Donald Trump and over objections of public health officials. Caitlin Owens of Axios and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss this and more. Also, Rovner interviews KHN’s Carmen Heredia Rodriguez, who wrote the latest KHN-NPR “Bill of the Month” installment about COVID testing that should have been free but was not.
Many Americans order drugs from Canada and other countries because they are cheaper, but U.S. authorities appear to be cracking down on the practice.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.